DRW Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-28,619
Closed -$3.46M 1529
2025
Q2
$3.46M Buy
28,619
+25,515
+822% +$2.88M 0.08% 140
2025
Q1
$346K Buy
+3,104
New +$330K 0.01% 399
2024
Q3
Sell
-39,405
Closed -$4.19M 680
2024
Q2
$4.19M Sell
39,405
-6,928
-15% -$695K 0.17% 98
2024
Q1
$4.48M Buy
46,333
+37,369
+417% +$3.83M 0.12% 73
2023
Q4
$905K Buy
8,964
+3,963
+79% +$383K 0.01% 152
2023
Q3
$509K Buy
5,001
+1,855
+59% +$188K 0.01% 214
2023
Q2
$317K Buy
3,146
+919
+41% +$91.9K 0.01% 248
2023
Q1
$205K Buy
+2,227
New +$194K ﹤0.01% 292
2022
Q1
Sell
-3,000
Closed -$262K 320
2021
Q4
$262K Buy
+3,000
New +$249K 0.01% 199

Other funds holding NVS

DRW Securities's NVS Position: Q3 2025 in Review

DRW Securities sold out of Novartis (NVS) in Q3 2025, closing a stake of 28,619 shares — an estimated $3.46M sold.

DRW Securities first reported a position in NVS in Q4 2021 and held it in 9 quarters. The position peaked at $4.48M in Q1 2024. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • DRW Securities reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 28,619 Novartis shares in Q3 2025, an estimated $3.46M.
  • DRW Securities first reported a position in Novartis in Q4 2021 and held it in 9 quarters.
  • DRW Securities's Novartis position peaked at $4.48M in Q1 2024.
  • 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.